Literature DB >> 30936025

Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up).

V Lavoue1, C Huchon2, C Akladios3, P Alfonsi4, N Bakrin5, M Ballester6, S Bendifallah7, P A Bolze8, F Bonnet9, C Bourgin10, N Chabbert-Buffet7, P Collinet10, B Courbiere11, T De la Motte Rouge12, M Devouassoux-Shisheboran13, C Falandry14, G Ferron15, L Fournier16, L Gladieff17, F Golfier8, S Gouy18, F Guyon19, E Lambaudie20, A Leary21, F Lecuru22, M A Lefrere-Belda23, E Leblanc24, A Lemoine9, F Narducci24, L Ouldamer25, P Pautier21, F Planchamp26, N Pouget27, I Ray-Coquard28, C Rousset-Jablonski28, C Senechal-Davin19, C Touboul29, I Thomassin-Naggara30, C Uzan31, B You32, E Daraï7.   

Abstract

Adjuvant chemotherapy by carboplatin and paclitaxel is recommended for all high-grade ovarian and tubal cancers (FIGO stages I-IIA) (grade A). After primary surgery is complete, 6 cycles of intravenous chemotherapy (grade A) are recommended, or a discussion with the patient about intraperitoneal chemotherapy, according to her risk-benefit ratio. After complete interval surgery for FIGO stage III, hyperthermic intraperitoneal chemotherapy (HIPEC) can be proposed, in accordance with the modalities of the OV-HIPEC trial (grade B). In cases of postoperative tumor residue or in FIGO stage IV tumors, chemotherapy associated with bevacizumab is recommended (grade A).
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Guidelines; Ovarian cancer; Primary peritoneal cancer; Surgery; Tubal cancer

Mesh:

Substances:

Year:  2019        PMID: 30936025     DOI: 10.1016/j.jogoh.2019.03.018

Source DB:  PubMed          Journal:  J Gynecol Obstet Hum Reprod        ISSN: 2468-7847


  6 in total

1.  Onco-gynecologic surgery in the COVID-19 era: Risks and precautions-A position paper from FRANCOGYN, SCGP, SFCO, and SFOG.

Authors:  Vincent Lavoué; Cherif Akladios; Laurence Gladieff; Jean-Marc Classe; Fabrice Lécuru; Pierre Collinet
Journal:  J Gynecol Obstet Hum Reprod       Date:  2020-05-11

2.  Multi-Disciplinary Care Planning of Ovarian Cancer in Older Patients: General Statement-A Position Paper from SOFOG-GINECO-FRANCOGYN-SFPO.

Authors:  Leila Bengrine; Naoual Bakrin; Frédérique Rousseau; Vincent Lavoué; Claire Falandry
Journal:  Cancers (Basel)       Date:  2022-03-02       Impact factor: 6.639

3.  Prolonged Exposition with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) May Provide Survival Benefit after Cytoreductive Surgery (CRS) in Advanced Primary Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.

Authors:  Miklos Acs; Zoltan Herold; Attila Marcell Szasz; Max Mayr; Sebastian Häusler; Pompiliu Piso
Journal:  Cancers (Basel)       Date:  2022-07-06       Impact factor: 6.575

4.  Residual Microscopic Peritoneal Metastases after Macroscopic Complete Cytoreductive Surgery for Advanced High-Grade Serous Ovarian Carcinoma: A Target for Folate Receptor Targeted Photodynamic Therapy?

Authors:  Morgane Moinard; Jeremy Augustin; Marine Carrier; Elisabeth Da Maïa; Alix Penel; Jérémie Belghiti; Maryam Nikpayam; Clémentine Gonthier; Geoffroy Canlorbe; Samir Acherar; Nadira Delhem; Céline Frochot; Catherine Uzan; Henri Azaïs
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-22

5.  Successful in vivo retrieval of oocytes after ovarian stimulation for fertility preservation before oophorectomy by laparotomy for a young patient with ovarian cancer: Case report and review of literature.

Authors:  Julie Benard; Isabelle Streuli; Antonella Biondo; Patrick Petignat; Manuela Undurraga Malinverno
Journal:  Gynecol Oncol Rep       Date:  2021-05-21

6.  Management and Survival of Elderly and Very Elderly Patients with Ovarian Cancer: An Age-Stratified Study of 1123 Women from the FRANCOGYN Group.

Authors:  Yolaine Joueidi; Ludivine Dion; Sofiane Bendifallah; Camille Mimoun; Alexandre Bricou; Krystel Nyangoh Timoh; Pierre Collinet; Cyril Touboul; Lobna Ouldamer; Henri Azaïs; Yohann Dabi; Cherif Akladios; Geoffroy Canlorbe; Pierre-Adrien Bolze; Hélène Costaz; Mathieu Mezzadri; Tristan Gauthier; Frederic Kridelka; Pauline Chauvet; Nicolas Bourdel; Martin Koskas; Xavier Carcopino; Emilie Raimond; Olivier Graesslin; Lise Lecointre; Marcos Ballester; Cyrille Huchon; Jean Levêque; Vincent Lavoué
Journal:  J Clin Med       Date:  2020-05-13       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.